View Future GrowthCumberland Pharmaceuticals 過去の業績過去 基準チェック /06Cumberland Pharmaceuticalsは0.9%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで8.7%毎年増加している。売上は成長しており、年平均1.7%の割合である。主要情報0.95%収益成長率-0.23%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率1.72%株主資本利益率-11.67%ネット・マージン-6.37%次回の業績アップデート05 May 2026最近の業績更新Cumberland Pharmaceuticals Inc. to Report Q1, 2026 Results on May 05, 2026Apr 29Full year 2025 earnings released: US$0.19 loss per share (vs US$0.46 loss in FY 2024) Mar 05Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2025 Results on Mar 03, 2026Feb 25Third quarter 2025 earnings released: US$0.13 loss per share (vs US$0.11 loss in 3Q 2024) Nov 06Cumberland Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 04, 2025Oct 29Second quarter 2025 earnings released Aug 06すべての更新を表示Recent updatesCumberland Pharmaceuticals Inc. to Report Q1, 2026 Results on May 05, 2026Apr 29Cumberland Pharmaceuticals Inc Announces Expanded Indication for Caldolor Ibuprofen InjectionApr 17Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 21, 2026Mar 10New major risk - Revenue and earnings growth Mar 09Full year 2025 earnings released: US$0.19 loss per share (vs US$0.46 loss in FY 2024) Mar 05New major risk - Revenue and earnings growth Mar 04Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2025 Results on Mar 03, 2026Feb 25Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% PoundingFeb 06Cumberland Pharmaceuticals Inc. Receives FDA Fast Track Designation for Its Ifetroban Duchenne Muscular Dystrophy ProgramFeb 04New minor risk - Share price stability Dec 16Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Shares Fly 26% But Investors Aren't Buying For GrowthDec 11Cumberland Pharmaceuticals Inc. Announces an Important Update Regarding its Caldolor®? (ibuprofen) InjectionDec 09Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?Nov 30Third quarter 2025 earnings released: US$0.13 loss per share (vs US$0.11 loss in 3Q 2024) Nov 06New major risk - Revenue and earnings growth Nov 05Cumberland Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 04, 2025Oct 29Cumberland Pharmaceuticals Inc. Adds Their Potent Antibativ®? to National Group Purchasing Agreement with Premier, IncOct 13Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S No Reason For ExcitementOct 08Cumberland Pharmaceuticals Announces Product Approval in MexicoOct 01Tabuk Pharmaceutical Manufacturing Company and Cumberland Pharmaceuticals Inc. Announces the Launch of Cumberland's Vibativ®? (Telavancin) Injection in Saudi ArabiaSep 30Second quarter 2025 earnings released Aug 06New major risk - Revenue and earnings growth Aug 06Insufficient new directors Aug 01Cumberland Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 05, 2025Jul 30New major risk - Share price stability Jun 30Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Not Doing Enough For Some Investors As Its Shares Slump 50%Jun 27Cumberland Pharmaceuticals Shares Phase 2 Fight Dmd Trial Results At the Parent Project Muscular Dystrophy Annual ConferenceJun 24Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?Jun 21Cumberland Pharmaceuticals Inc. Announces the Publication of Its Study InvestigatingCaldolor (Intravenous Ibuprofen) in Older PatientsMay 28Cumberland Pharmaceuticals Inc. Partners with Qureight to Advance Innovative Idiopathic Pulmonary Fibrosis Treatment ResearchMay 14Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30%May 13First quarter 2025 earnings released: EPS: US$0.084 (vs US$0.14 loss in 1Q 2024) May 07Cumberland Pharmaceuticals Inc. to Report Q1, 2025 Results on May 06, 2025Apr 30Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 22, 2025Mar 11Full year 2024 earnings released: US$0.46 loss per share (vs US$0.44 loss in FY 2023) Mar 05Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 117%Mar 01Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2024 Results on Mar 04, 2025Feb 26Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?Feb 21Cumberland Pharmaceuticals Inc. and SciClone Pharmaceuticals (Holdings) Limited Announce the National Medical Products Administration Approval of Cumberland's Vibativ® (Telavancin) Injection in ChinaFeb 18Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 Fight DMD Trial in Duchenne Muscular Dystrophy Heart DiseaseFeb 04Improved Revenues Required Before Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock's 26% Jump Looks JustifiedJan 15New major risk - Share price stability Dec 10Cumberland Pharmaceuticals Inc. Announces FDA Approves Supplemental New Drug Application (sNDA) for Its Acetadote (N-Acetylcysteine for Injection) ProductDec 10Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) Nov 10Cumberland Pharmaceuticals Announces New Study Compares Caldolor® (ibuprofen injection) to KetorolacNov 06Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?Nov 04Cumberland Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024Nov 01Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.061 profit in 2Q 2023) Aug 07Cumberland Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 06, 2024Jul 31First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2023) May 08Cumberland Pharmaceuticals Inc. to Report Q1, 2024 Results on May 07, 2024May 01Cumberland Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $5.8 million.Mar 21New minor risk - Share price stability Mar 15Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 23, 2024Mar 14Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?Mar 07Full year 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in FY 2022) Mar 06Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 05, 2024Feb 28Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift SharesJan 09New minor risk - Shareholder dilution Dec 18Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.028 loss in 3Q 2022) Nov 10Cumberland Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 07, 2023Nov 01Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of AgeOct 11+ 1 more updateNew minor risk - Share price stability Oct 08Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/SOct 02Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?Aug 10Second quarter 2023 earnings released: EPS: US$0.061 (vs US$0.091 loss in 2Q 2022) Aug 09Cumberland Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 08, 2023Aug 03Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric DrugsJun 27Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary FibrosisMay 24U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for CaldolorMay 16First quarter 2023 earnings released: EPS: US$0.013 (vs US$0.094 loss in 1Q 2022) May 10Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?Mar 18Full year 2022 earnings released: US$0.38 loss per share (vs US$0.37 loss in FY 2021) Mar 08Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of DirectorsJan 19Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug AdministrationDec 13Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021) Nov 19Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021) Nov 10Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?Nov 02Cumberland Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022Nov 02Second quarter 2022 earnings released: US$0.091 loss per share (vs US$0.049 profit in 2Q 2021) Aug 11Cumberland Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022Aug 03Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of DirectorsJul 21Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)Jul 20Cumberland Pharmaceuticals Inc. Announces Executive ChangesJun 05First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 12Cumberland Pharmaceuticals Inc. to Report Q1, 2022 Results on May 10, 2022May 04Insufficient new directors Apr 27Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?Apr 15Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle EastApr 01Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 10Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2021 Results on Mar 08, 2022Mar 03Now 22% undervalued Jan 14Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) acquired SANCUSO from Kyowa Kirin, Inc. for $17 million.Jan 06Checking In On Cumberland Pharmaceuticals Jan 04Cumberland Pharmaceuticals Inc. Receives FDA Approval for Expanded Labeling for Caldolor®Dec 01Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.083 loss in 3Q 2020) Nov 13Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?Nov 09Consensus forecasts updated Aug 17Second quarter 2021 earnings released: EPS US$0.049 (vs US$0.11 loss in 2Q 2020) Aug 12収支内訳Cumberland Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGS:CPIX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 2545-331630 Sep 2541-328530 Jun 2542-328531 Mar 2541-328531 Dec 2438-628530 Sep 2437-1129530 Jun 2438-1029531 Mar 2439-829531 Dec 2340-629630 Sep 2339-228630 Jun 2341-227631 Mar 2340-427631 Dec 2242-627730 Sep 2241-727730 Jun 2238-926731 Mar 2237-726631 Dec 2136-625630 Sep 2138-325530 Jun 2139-325531 Mar 2140-525531 Dec 2037-725630 Sep 2036-825630 Jun 2034-1025731 Mar 2034-1025731 Dec 1934-925730 Sep 1939-827830 Jun 1940-628731 Mar 1941-629731 Dec 1829-1124830 Sep 1839-630630 Jun 1842-532531 Mar 1840-931531 Dec 1741-831430 Sep 1739-829430 Jun 1736-727431 Mar 1735-225331 Dec 1633-123330 Sep 1632021230 Jun 1631021331 Mar 1633022331 Dec 1534122430 Sep 1535122430 Jun 15372234質の高い収益: CPIXは現在利益が出ていません。利益率の向上: CPIXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CPIXは利益を出していないが、過去 5 年間で年間0.9%の割合で損失を削減してきた。成長の加速: CPIXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: CPIXは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -3.3% ) と比較することは困難です。株主資本利益率高いROE: CPIXは現在利益が出ていないため、自己資本利益率 ( -11.67% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/03 11:43終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cumberland Pharmaceuticals Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Andrew D'SilvaB. Riley Securities, Inc.David WindleyJefferies LLCMarc GoodmanUBS Investment Bank1 その他のアナリストを表示
Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% PoundingFeb 06
Cumberland Pharmaceuticals Inc. Receives FDA Fast Track Designation for Its Ifetroban Duchenne Muscular Dystrophy ProgramFeb 04
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Shares Fly 26% But Investors Aren't Buying For GrowthDec 11
Cumberland Pharmaceuticals Inc. Announces an Important Update Regarding its Caldolor®? (ibuprofen) InjectionDec 09
Cumberland Pharmaceuticals Inc. Adds Their Potent Antibativ®? to National Group Purchasing Agreement with Premier, IncOct 13
Tabuk Pharmaceutical Manufacturing Company and Cumberland Pharmaceuticals Inc. Announces the Launch of Cumberland's Vibativ®? (Telavancin) Injection in Saudi ArabiaSep 30
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Not Doing Enough For Some Investors As Its Shares Slump 50%Jun 27
Cumberland Pharmaceuticals Shares Phase 2 Fight Dmd Trial Results At the Parent Project Muscular Dystrophy Annual ConferenceJun 24
Cumberland Pharmaceuticals Inc. Announces the Publication of Its Study InvestigatingCaldolor (Intravenous Ibuprofen) in Older PatientsMay 28
Cumberland Pharmaceuticals Inc. Partners with Qureight to Advance Innovative Idiopathic Pulmonary Fibrosis Treatment ResearchMay 14
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30%May 13
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 117%Mar 01
Cumberland Pharmaceuticals Inc. and SciClone Pharmaceuticals (Holdings) Limited Announce the National Medical Products Administration Approval of Cumberland's Vibativ® (Telavancin) Injection in ChinaFeb 18
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 Fight DMD Trial in Duchenne Muscular Dystrophy Heart DiseaseFeb 04
Improved Revenues Required Before Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock's 26% Jump Looks JustifiedJan 15
Cumberland Pharmaceuticals Inc. Announces FDA Approves Supplemental New Drug Application (sNDA) for Its Acetadote (N-Acetylcysteine for Injection) ProductDec 10
Cumberland Pharmaceuticals Announces New Study Compares Caldolor® (ibuprofen injection) to KetorolacNov 06
Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.061 profit in 2Q 2023) Aug 07
Cumberland Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $5.8 million.Mar 21
Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of AgeOct 11+ 1 more update
Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/SOct 02
Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric DrugsJun 27
Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary FibrosisMay 24
U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for CaldolorMay 16
Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of DirectorsJan 19
Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug AdministrationDec 13
Second quarter 2022 earnings released: US$0.091 loss per share (vs US$0.049 profit in 2Q 2021) Aug 11
Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle EastApr 01
Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) acquired SANCUSO from Kyowa Kirin, Inc. for $17 million.Jan 06